Paul D. Goldenheim, M.D.
Chairman - Promedior, Inc.
Former President - TransForm Pharmaceuticals, Inc.
Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies. He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. He also serves on several non-profit boards. Dr. Goldenheim obtained both his A.B. and M.D. degrees from Harvard.
Amir Nashat, Ph.D.
General Partner - Polaris Venture Partners
Amir Nashat, Ph.D., is a General Partner in the Boston office of Polaris Venture Partners. He joined Polaris in April 2002 and focuses on investments in the life sciences.
Prior to joining Polaris, Dr. Nashat completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. His doctoral research focused on information flow through neurons, neural implants, and neural tissue engineering. During his time at M.I.T., he completed an internship in the London office of Goldman, Sachs & Company, where he worked on interest rate derivative products.
Dr. Nashat currently represents Polaris as a Director of Athenix Corporation, eNOS Pharmaceuticals,
Hydra Biosciences, Promedior Inc., Pervasis Therapeutics Inc. (where he was founding
President), T2 Biosystems and WaveRx. Additionally, he is Board Observer
to GI Dynamics, and supports Polaris' Investment in Advion. He currently serves
on the Board of the New England Venture Capital Association, on the Advisory Board
of the Simmons School of Management Entrepreneurship Initiative, and is a Catalyst
for the Deshpande Center for Technological Innovation at M.I.T.
Prior to obtaining his Ph.D. at MIT, Dr. Nashat earned both his M.S. and B.S. in Materials
Science and Mechanical Engineering at the University of California, Berkeley.
James W. Broderick, M.D.
General Partner - Morgenthaler Ventures
James Broderick, M.D., is a General Partner at Morgenthaler Ventures and invests in companies developing innovative biotech and medical device therapeutic products.
He was a co-founder of Promedior. He is also founding CEO of Innovative Metabolics, and an investor and board member of several other novel biotech and medical device companies including
OncoMed Pharmaceuticals, Bayhill Therapeutics, Spine Wave, Symphony Medical, and
Trellis Bioscience. Previously, Dr. Broderick served as a director at NexTag.
He opened Morgenthaler's Boston office in 2005 after spending several years in Silicon Valley. Trained as a physician and an engineer, Dr. Broderick is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine). He was a member of the Kauffman Fellows Program, a two year educational fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership designed to train future venture capitalists and leaders of high growth companies. Dr. Broderick
had previously worked as a consultant at Mercer Management Consulting, and as a resident at Duke University Medical Center.
Larry Kauvar, Ph.D.
Vice Chairman - Trellis Bioscience, Inc.
Larry Kauvar, Ph.D., serves as Vice Chairman and Chief Scientific Officer of Trellis Bioscience, a company he founded in 1998. Trellis is a venture backed biotechnology company that discovers human antibodies directly from patients blood. Prior to Trellis, Dr. Kauvar served as Chief Scientific Officer of Telik (Nasdaq: TELK) for 12 years, a company he founded in 1986. Dr. Kauvar received his Ph.D. from Yale and his BA from Harvard. He was a Jane Coffin Childs postdoctoral fellow at Caltech, and a Weingart Foundation scholar at UCSF prior to starting Telik.
HAROLD (hAL) r. wERNER
General Partner - HealthCare Ventures, LLC
Mr. Werner is a General Partner of HealthCare Ventures. He is a member of the Board of Directors of Aciex, Inc., DecImmune Therapeutics, Innomab, Oriel Therapeutics, Inc., Promedior, Inc., Stemgent, Inc., Tetralogic Pharmaceuticals, Inc., and Xencor, Inc., all private companies. He is also a member of the Board of Directors of MiddleBrook Pharmaceuticals, a public company. Mr. Werner received his MBA from the Harvard Graduate School of Business and his BS and MS degrees from Princeton University.
timothy j. pelura, ph.D.
President & CEO - Promedior, Inc.
Tim Pelura, Ph.D. is Promedior's President and CEO. He has over 30 years of experience in the pharmaceutical and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas. As Chief Technology Officer at Kereos Dr. Pelura was responsible for all R&D activities for their oncology, cardiology, and molecular imaging programs. Prior to joining Kereos, he served as President and COO of Provasis Therapeutics, a developer of interventional neurosurgical devices. Dr. Pelura held executive R&D positions at Neuron Therapeutics and Alliance Pharmaceutical Corp. Earlier, Dr. Pelura worked in various R&D capacities at KabiVitrum and Pharmacia. Dr. Pelura holds a Ph.D. in chemistry from Rutgers University.